{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T06:10:02Z","timestamp":1744351802394,"version":"3.40.4"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic & Medicinal Chemistry Letters"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.bmcl.2025.130192","type":"journal-article","created":{"date-parts":[[2025,3,23]],"date-time":"2025-03-23T04:46:06Z","timestamp":1742705166000},"page":"130192","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Discovery of liver-selective glucokinase activators comprising N-(4-alkylthiazol-2-yl)benzamides and N-(3-alkyl-1,2,4-thiadiazol-5-yl)benzamides for the treatment of metabolic disorders"],"prefix":"10.1016","volume":"122","author":[{"given":"David S.","family":"Yoon","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shung","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sean S.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rebecca A.","family":"Smirk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert P.","family":"Brigance","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Meng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Shi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shiwei","family":"Tao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arvind","family":"Mathur","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helen Grace","family":"Catanio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen","family":"Kalinowski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rachel","family":"Zebo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacob","family":"Zalaznick","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bradley","family":"Zinker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa M.","family":"Kopcho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kamelia","family":"Behnia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carrie","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven A.","family":"Spronk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanou","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan","family":"Josephs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Evan B.","family":"Janovitz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Punit","family":"Marathe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean","family":"Whaley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joel C.","family":"Barrish","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Kirby","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter T.W.","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bmcl.2025.130192_bb0005","doi-asserted-by":"crossref","first-page":"2730","DOI":"10.1016\/S0021-9258(18)93432-0","article-title":"Metabolism of glucose in the islets of Langerhans","volume":"243","author":"Matschinsky","year":"1968","journal-title":"J Biol Chem"},{"key":"10.1016\/j.bmcl.2025.130192_bb0010","first-page":"3278","article-title":"High km glucose-phosphorylating (glucokinase) activities in a range of tumor cell lines and inhibition of rates of tumor growth by the specific enzyme inhibitor mannoheptulose","volume":"55","author":"Board","year":"1995","journal-title":"Cancer Res"},{"key":"10.1016\/j.bmcl.2025.130192_bb0015","doi-asserted-by":"crossref","first-page":"148","DOI":"10.3389\/fphys.2019.00148","article-title":"The central role of Glucokinase in glucose homeostasis: a perspective 50 years after demonstrating the presence of the enzyme in islets of Langerhans","volume":"10","author":"Matschinsky","year":"2019","journal-title":"Front Physiol"},{"key":"10.1016\/j.bmcl.2025.130192_bb0020","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1042\/BJ20080595","article-title":"Glucokinase and molecular aspects of liver glycogen metabolism","volume":"414","author":"Agius","year":"2008","journal-title":"Biochem J"},{"key":"10.1016\/j.bmcl.2025.130192_bb0025","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/nrd2850","article-title":"Assessing the potential of glucokinase activators in diabetes therapy","volume":"8","author":"Matschinsky","year":"2009","journal-title":"Nat Rev Drug Discov"},{"issue":"suppl 3","key":"10.1016\/j.bmcl.2025.130192_bb0030","doi-asserted-by":"crossref","first-page":"S394","DOI":"10.2337\/diabetes.51.2007.S394","article-title":"Regulation of pancreatic \u03b2-cell glucokinase from basics to therapeutics","volume":"51","author":"Matschinsky","year":"2002","journal-title":"Diabetes"},{"key":"10.1016\/j.bmcl.2025.130192_bb0035","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1126\/science.1084073","article-title":"Allosteric activators of glucokinase: potential role in diabetes therapy","volume":"301","author":"Grimsby","year":"2003","journal-title":"Science"},{"key":"10.1016\/j.bmcl.2025.130192_bb0040","doi-asserted-by":"crossref","first-page":"535","DOI":"10.2337\/diabetes.53.3.535","article-title":"Stimulation of hepatocyte glucose metabolism by novel small molecule Glucokinase activators","volume":"53","author":"Brocklehurst","year":"2004","journal-title":"Diabetes"},{"key":"10.1016\/j.bmcl.2025.130192_bb0045","doi-asserted-by":"crossref","first-page":"37668","DOI":"10.1074\/jbc.M605186200","article-title":"An allosteric activator of Glucokinase impairs the interaction of Glucokinase and Glucokinase regulatory protein and regulates glucose metabolism","volume":"281","author":"Futamura","year":"2006","journal-title":"J Biol Chem"},{"key":"10.1016\/j.bmcl.2025.130192_bb0050","doi-asserted-by":"crossref","first-page":"585","DOI":"10.2174\/1389557514666140722082713","article-title":"Recent updates on Glucokinase activators for the treatment of type 2 diabetes mellitus","volume":"14","author":"Grewala","year":"2014","journal-title":"Mini-Rev Med Chem"},{"key":"10.1016\/j.bmcl.2025.130192_bb0055","first-page":"147","article-title":"Glucokinase activators for the treatment of diabetes","volume":"52","author":"Dransfield","year":"2017","journal-title":"Med Chem Rev"},{"key":"10.1016\/j.bmcl.2025.130192_bb0060","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1517\/13543776.2014.965680","article-title":"Lessons from Glucokinase activators: the problem of declining efficacy","volume":"24","author":"Agius","year":"2014","journal-title":"Expert Opin Ther Patents"},{"key":"10.1016\/j.bmcl.2025.130192_bb0065","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2024.116499","article-title":"Compromised chronic efficacy of a glucokinase activator AZD1656 in mouse models for common human GCKR variants","volume":"229","author":"Ford","year":"2024","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.bmcl.2025.130192_bb0070","doi-asserted-by":"crossref","first-page":"2164","DOI":"10.2337\/diabetes.53.8.2164","article-title":"Severe persistent hyperinsulinemic hypoglycemia due to a De novo glucokinase mutation","volume":"53","author":"Cuesta-Munoz","year":"2004","journal-title":"Diabetes"},{"key":"10.1016\/j.bmcl.2025.130192_bb0075","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.2337\/dc11-1200","article-title":"Effects of MK-0941, a novel Glucokinase activator, on glycemic control in insulin-treated patients with type 2 diabetes","volume":"34","author":"Meininger","year":"2011","journal-title":"Diabetes Care"},{"key":"10.1016\/j.bmcl.2025.130192_bb0080","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1111\/dom.12088","article-title":"Dose-ranging study with the Glucokinase activator AZD1656 in patients with type 2 diabetes mellitus on metformin","volume":"15","author":"Wilding","year":"2013","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.bmcl.2025.130192_bb0085","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1111\/dom.12474","article-title":"Two dose-ranging studies with PF-04937319, a systemic partial activator of glucokinase, as add-on therapy to metformin in adults with type 2 diabetes","volume":"17","author":"Amin","year":"2015","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.bmcl.2025.130192_bb0090","doi-asserted-by":"crossref","first-page":"4291","DOI":"10.1021\/acs.jmedchem.1c02110","article-title":"Discovery of a partial glucokinase activator clinical candidate: diethyl ((3-(3-((5-(azetidine-1-carbonyl)pyrazin-2-yl)oxy)-5-isopropoxybenzamido)-1H-pyrazol-1-yl)methyl)phosphonate (BMS-820132)","volume":"65","author":"Shi","year":"2022","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2025.130192_bb0095","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.ejmech.2017.03.042","article-title":"Discovery of liver-directed glucokinase activator having anti-hyperglycemic effect without hypoglycemia","volume":"133","author":"Deshpande","year":"2017","journal-title":"Eur J Med Chem"},{"issue":"5","key":"10.1016\/j.bmcl.2025.130192_bb0100","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0097139","article-title":"The Hepatoselective glucokinase activator PF-04991532 ameliorates hyperglycemia without causing hepatic steatosis in diabetic rats","volume":"9","author":"Erion","year":"2014","journal-title":"PLoS ONE"},{"key":"10.1016\/j.bmcl.2025.130192_bb0105","doi-asserted-by":"crossref","first-page":"571","DOI":"10.3390\/ijms25010571","article-title":"New-generation glucokinase activators: potential game-changers in type 2 diabetes treatment","volume":"25","author":"Haddad","year":"2024","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.bmcl.2025.130192_bb0110","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1038\/s41591-022-01802-6","article-title":"Dorzagliatin in drug-na\u00efve patients with type 2 diabetes: a randomized, double-blind, placebo-controlled phase 3 trial","volume":"28","author":"Zhu","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.bmcl.2025.130192_bb0115","doi-asserted-by":"crossref","first-page":"960","DOI":"10.2337\/dc20-2684","article-title":"The SimpliciT1 study: a randomized, double-blind, placebo-controlled phase 1b\/2 adaptive study of TTP399, a hepatoselective glucokinase activator, for adjunctive treatment of type 1 diabetes","volume":"44","author":"Klein","year":"2021","journal-title":"Diabetes Care"},{"key":"10.1016\/j.bmcl.2025.130192_bb0120","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1111\/dom.14909","article-title":"A multicentre, randomized, double-blind, parallel, active- and placebo-controlled phase 3 clinical study of the glucokinase activator PB-201 in treatment-naive patients with type 2 diabetes mellitus: a study protocol","volume":"25","author":"Du","year":"2023","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.bmcl.2025.130192_bb0125","unstructured":"Tandem GK enzymatic assay: All reagents were acquired from Sigma-Aldrich. Human and murine GK was produced in-house by purification of full-length human liver GK that had been expressed in E. coli. Activity\/activation assays were performed at room temperature for 10 min. Reaction mixtures contained 25 mM HEPES (pH 7.1), 3 mM ATP, 3.6 mM MgCl2, 1 mM DTT, and recombinant human hepatic GK (15 nM) in a total volume of 20 \u03bcL in a 384-well black microplate with a clear bottom. The activity of GK was quenched with 5 \u03bcL of 225 mM EDTA. The resultant G6P was then incubated in situ with 25 \u03bcL of the coupling reaction mixture (0.175 units G6P dehydrogenase, 677 \u03bcM thio-NAD), and the presence of thio-NADH was detected by absorbance measurements at 405 nm on a Spectramax Plus 384 absorbance plate reader (Molecular Devices)."},{"key":"10.1016\/j.bmcl.2025.130192_bb0130","unstructured":"mPK = single dose mouse pharmacokinetic studies. Dose = 10 mg\/kg; dose volume (p.o.) = 5 mL\/kg; liver collection time point = 1 h; vehicle (solution) = Cremophor\/PEG400\/water 10\/40\/50."},{"key":"10.1016\/j.bmcl.2025.130192_bb0135","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1021\/jm2014887","article-title":"Discovery of (S)-6-(3-cyclopentyl-2-(4-(trifluoromethyl)-1H-imidazol-1-yl)propanamido)nicotinic acid as a hepatoselective glucokinase activator clinical candidate for treating type 2 diabetes mellitus","volume":"55","author":"Pfefferkorn","year":"2012","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2025.130192_bb0140","doi-asserted-by":"crossref","first-page":"857","DOI":"10.2174\/1568026611313070008","article-title":"Medicinal chemistry design principles for liver targeting through OATP transporters","volume":"13","author":"Tu","year":"2013","journal-title":"Curr Top Med Chem"},{"key":"10.1016\/j.bmcl.2025.130192_bb0145","doi-asserted-by":"crossref","first-page":"5971","DOI":"10.1073\/pnas.79.19.5971","article-title":"SOS chromotest, a direct assay of induction of an SOS function in Escherichia coli K-12 to measure genotoxicity","volume":"79","author":"Quillardet","year":"1982","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.bmcl.2025.130192_bb0150","unstructured":"Acute diet induced obese (DIO) mouse oral glucose tolerance test (OGTT) study parameters: Dose (p.o.) = 3.0 \u03bcmol\/kg; animal model = C57BL\/6J DIO (age 20 wks); diet: 16 wks on 60 kcal% HF diet (D12492); fasting: overnight; vehicle = 40%PEG400: 10% Cremophor: 50% H2O."},{"key":"10.1016\/j.bmcl.2025.130192_bb0155","unstructured":"Acute high dose diet induced obese (DIO) mouse non-OGTT study parameters: Dose = 30, 100 \u03bcmol\/kg; animal model = C57BL\/6J DIO (age 24 wks); diet: 18 wks on 60 kcal% HF diet (D12492); fasting: overnight; n = 10; vehicle = 40%PEG400: 10% Cremaphore: 50% dH2O; dose volume (p.o.) = 5 mL\/kg; insulin response measured at time points (min.) = 0.0, 30, 60, 120, 180 (sacrifice\/tissue harvest); insulin elevation observed at time point = 30 min."},{"key":"10.1016\/j.bmcl.2025.130192_bb0160","unstructured":"Single dose rat pharmacokinetic study. Dose = 10 mg\/kg; dose volume (p.o.) = 5 mL\/kg; liver collection time point = 4 h; vehicle (solution) = Cremophor\/PEG400\/water 10\/40\/50."},{"key":"10.1016\/j.bmcl.2025.130192_bb0165","doi-asserted-by":"crossref","first-page":"2953","DOI":"10.1002\/jps.23614","article-title":"Plasma protein binding: from discovery to development","volume":"102","author":"Bohnert","year":"2013","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.bmcl.2025.130192_bb0170","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1038\/nrd3287","article-title":"The effect of plasma protein binding on in vivo efficacy: misconceptions in drug discovery","volume":"9","author":"Smith","year":"2010","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.bmcl.2025.130192_bb0175","unstructured":"SFC separation conditions: column: Chiralpak AS-H, 250 X 21 cm ID, 5mm; flow rate: 60.0 mL\/min, 150 bar BP, 35 \u00b0C; mobile phase: 30% 2:1 MeOH-iPrOH\/70% CO2; detector wavelength: 220 nm."}],"container-title":["Bioorganic & Medicinal Chemistry Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X25001015?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X25001015?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T05:47:47Z","timestamp":1744350467000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960894X25001015"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":35,"alternative-id":["S0960894X25001015"],"URL":"https:\/\/doi.org\/10.1016\/j.bmcl.2025.130192","relation":{},"ISSN":["0960-894X"],"issn-type":[{"type":"print","value":"0960-894X"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Discovery of liver-selective glucokinase activators comprising N-(4-alkylthiazol-2-yl)benzamides and N-(3-alkyl-1,2,4-thiadiazol-5-yl)benzamides for the treatment of metabolic disorders","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmcl.2025.130192","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"130192"}}